Palisade Bio (NASDAQ:PALI) Now Covered by Brookline Capital Management

Equities research analysts at Brookline Capital Management assumed coverage on shares of Palisade Bio (NASDAQ:PALI) in a research note issued on Wednesday,Benzinga reports. The brokerage set a “buy” rating and a $38.00 price target on the stock.

Separately, Maxim Group dropped their target price on shares of Palisade Bio from $22.50 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th.

Palisade Bio Stock Performance

Shares of PALI stock opened at $2.44 on Wednesday. The stock has a 50 day moving average price of $3.23 and a 200 day moving average price of $4.05. Palisade Bio has a 52-week low of $2.18 and a 52-week high of $22.35. The firm has a market capitalization of $3.25 million, a P/E ratio of -0.17 and a beta of 1.36.

Palisade Bio (NASDAQ:PALI) last released its earnings results on Tuesday, November 12th. The company reported ($2.32) earnings per share for the quarter, topping the consensus estimate of ($3.35) by $1.03. As a group, sell-side analysts forecast that Palisade Bio will post -13.11 EPS for the current year.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.